The total return over the past 12 months is +23.00% vs. +16.94% for the S&P 500. So far it's up +0.95% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +23.00% | (21.95%) | (32.60%) | N/A | N/A | N/A |
| Total Return CAGR | +23.00% | (21.95%) | (32.60%) | N/A | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Acumen Pharmaceuticals, Inc. (ABOS)
| Year | Start price | End price | ABOS Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $2.11 | $2.13 | +0.95% | +14.51% | (13.56%) |
| 2025 | $1.72 | $2.11 | +22.67% | +17.72% | +4.95% |
| 2024 | $3.84 | $1.72 | (55.21%) | +24.89% | (80.10%) |
| 2023 | $5.40 | $3.84 | (28.89%) | +26.19% | (55.08%) |
| 2022 | $6.76 | $5.40 | (20.12%) | (18.17%) | (1.95%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
